Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the world's leading drugmakers, missed last ...

AstraZeneca, said: "Our company delivered a very strong performance in 2024 with Total Revenue and Core EPS up 21% and 19% respectively. We also delivered nine positive high value Phase III ...

Rare Disease Revenue: $8.8 billion in 2024, up 16%. AstraZeneca PLC (NASDAQ:AZN) reported a strong financial performance in 2024, with total revenue up 21% and core EPS up 19%, indicating robust ...

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

Pharmaceutical giant AstraZeneca announced its fourth quarter and full year 2024 earnings on Thursday. Product sales for the fourth quarter came up to $13.4 billion (€12.9bn), which was a rise ...

AstraZeneca continues to fully cooperate with the Chinese authorities. In December 2024 AstraZeneca announced the appointment of Iskra Reic as Executive Vice President, International, which ...

2024 was a very strong year for our company ... which to the best of our knowledge relates to Imfinzi and Imjudo. So if actually AstraZeneca was found liable, a fine of between one to five ...

BioPharmaceuticals Revenue: $21.9 billion in 2024, up 21%. Rare Disease Revenue: $8.8 billion in 2024, up 16%. AstraZeneca PLC (NASDAQ:AZN) reported a strong financial performance in 2024, with total ...

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary Financial performance for FY 2024 (Growth numbers at constant exchange rates) Total Revenue up 21% to $54,073m ...

Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary Financial performance for FY 2024 (Growth numbers at constant exchange ...